Go Pro
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel Free RADX Stock Alerts

Radiopharm Theranostics (RADX) Financials

Radiopharm Theranostics logo
$4.28 -0.15 (-3.39%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$4.63 +0.35 (+8.27%)
As of 06:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Radiopharm Theranostics

Annual Income Statements for Radiopharm Theranostics

This table shows Radiopharm Theranostics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -29 -49 -49
Consolidated Net Income / (Loss)		 -35 -48 -38
Net Income / (Loss) Continuing Operations		 -29 -49 -49
Total Pre-Tax Income 		-35 -48 -38
Total Operating Income		 -34 -47 -38
Total Gross Profit		 0.29 0.30 0.04
Total Revenue		 0.29 0.30 3.63
Operating Revenue		 0.29 0.30 3.63
Total Cost of Revenue		 0.26 0.00 3.59
Operating Cost of Revenue		 0.26 0.00 3.59
Total Operating Expenses		 35 40 44
Selling, General & Admin Expense		 12 17 17
Research & Development Expense		 23 23 28
Total Other Income / (Expense), net		 5.98 -9.50 -4.13
Interest Expense		 0.09 0.64 0.07
Other Income / (Expense), net		 6.06 -8.86 -4.07
Income Tax Expense		 0.04 0.10 0.10
Basic Earnings per Share		 ($11.32) ($12.41) ($1.76)
Weighted Average Basic Shares Outstanding		 - - 2.36B
Diluted Earnings per Share		 ($11.32) ($12.41) ($1.76)
Weighted Average Diluted Shares Outstanding		 - - 2.36B
Weighted Average Basic & Diluted Shares Outstanding		 - - 2.36B

Quarterly Income Statements for Radiopharm Theranostics

No quarterly income statements for Radiopharm Theranostics are available.

Annual Cash Flow Statements for Radiopharm Theranostics

This table details how cash moves in and out of Radiopharm Theranostics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 -0.05 -0.12 -0.22
Net Cash From Operating Activities		 0.00 0.00 0.00
Net Cash From Continuing Operating Activities		 0.00 0.00 0.00
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00
Net Cash From Investing Activities		 -0.05 0.00 0.00
Net Cash From Continuing Investing Activities		 -0.05 0.00 0.00
Purchase of Property, Plant & Equipment		 -0.05 0.00 0.00
Net Cash From Financing Activities		 0.00 -0.12 -0.22
Net Cash From Continuing Financing Activities		 0.00 -0.12 -0.22
Issuance of Debt		 0.00 -0.12 -0.22
Cash Interest Received		 0.15 0.05 0.80

Quarterly Cash Flow Statements for Radiopharm Theranostics

No quarterly cash flow statements for Radiopharm Theranostics are available.

Annual Balance Sheets for Radiopharm Theranostics

This table presents Radiopharm Theranostics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2025
Period end date 6/30/2024 6/30/2025
Total Assets		 72 86
Total Current Assets		 23 40
Cash & Equivalents		 19 29
Accounts Receivable		 0.99 10
Other Current Assets		 0.29 0.34
Plant, Property, & Equipment, net		 0.06 0.05
Plant, Property & Equipment, gross		 0.06 0.05
Total Noncurrent Assets		 49 47
Intangible Assets		 49 47
Other Noncurrent Operating Assets		 0.04 0.00
Total Liabilities & Shareholders' Equity		 72 86
Total Liabilities		 45 44
Total Current Liabilities		 18 15
Short-Term Debt		 6.32 3.42
Accounts Payable		 11 9.34
Current Deferred Revenue		 0.00 1.72
Other Taxes Payable		 0.40 0.45
Total Noncurrent Liabilities		 27 29
Long-Term Debt		 27 29
Other Noncurrent Operating Liabilities		 0.00 0.00
Total Equity & Noncontrolling Interests		 27 43
Total Preferred & Common Equity		 28 45
Total Common Equity		 28 45
Common Stock		 101 177
Accumulated Other Comprehensive Income / (Loss)		 -111 -146
Other Equity Adjustments		 39 14
Noncontrolling Interest		 -0.77 -1.92

Quarterly Balance Sheets for Radiopharm Theranostics

No quarterly balance sheets for Radiopharm Theranostics are available.

Annual Metrics And Ratios for Radiopharm Theranostics

This table displays calculated financial ratios and metrics derived from Radiopharm Theranostics' official financial filings.

Metric 2023 2024 2025
Period end date 6/30/2023 6/30/2024 6/30/2025
DEI Shares Outstanding		 0.00 0.00 0.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00
Growth Metrics		 - - -
Revenue Growth		 0.00% 2.35% 1,114.27%
EBITDA Growth		 0.00% -97.26% 24.66%
EBIT Growth		 0.00% -97.26% 24.66%
NOPAT Growth		 0.00% -36.89% 19.14%
Net Income Growth		 0.00% -38.54% 20.04%
EPS Growth		 0.00% -9.63% 85.82%
Operating Cash Flow Growth		 0.00% 0.00% 0.00%
Free Cash Flow Firm Growth		 0.00% 0.00% 53.82%
Invested Capital Growth		 0.00% 0.00% 16.95%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00%
Profitability Metrics		 - - -
Gross Margin		 100.00% 100.00% 1.08%
EBITDA Margin		 -9,722.49% -18,738.29% -1,162.64%
Operating Margin		 -11,796.15% -15,777.22% -1,050.63%
EBIT Margin		 -9,722.49% -18,738.29% -1,162.64%
Profit (Net Income) Margin		 -11,838.59% -16,024.28% -1,055.27%
Tax Burden Percent		 100.11% 100.20% 100.27%
Interest Burden Percent		 121.63% 85.34% 90.52%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -168.58% -62.83%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -420.01% -219.49%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -182.02% -46.37%
Return on Equity (ROE)		 0.00% -350.59% -109.20%
Cash Return on Invested Capital (CROIC)		 0.00% -368.58% -78.46%
Operating Return on Assets (OROA)		 0.00% -77.84% -53.30%
Return on Assets (ROA)		 0.00% -66.56% -48.38%
Return on Common Equity (ROCE)		 0.00% -360.45% -113.38%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -24 -33 -27
NOPAT Margin		 -8,257.30% -11,044.06% -735.44%
Net Nonoperating Expense Percent (NNEP)		 0.00% 251.43% 156.66%
Return On Investment Capital (ROIC_SIMPLE)		 - -54.37% -35.64%
Cost of Revenue to Revenue		 87.99% 0.00% 98.92%
SG&A Expenses to Revenue		 4,183.57% 5,649.72% 464.71%
R&D to Revenue		 7,741.00% 7,715.28% 757.28%
Operating Expenses to Revenue		 11,924.57% 13,364.99% 1,221.99%
Earnings before Interest and Taxes (EBIT)		 -28 -56 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -28 -56 -42
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 1.22 0.75
Long-Term Debt to Equity		 0.00 0.99 0.67
Financial Leverage		 0.00 0.43 0.21
Leverage Ratio		 0.00 2.63 2.26
Compound Leverage Factor		 0.00 2.25 2.04
Debt to Total Capital		 0.00% 55.00% 42.81%
Short-Term Debt to Total Capital		 0.00% 10.40% 4.56%
Long-Term Debt to Total Capital		 0.00% 44.60% 38.25%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% -1.27% -2.56%
Common Equity to Total Capital		 0.00% 46.27% 59.75%
Debt to EBITDA		 0.00 -0.60 -0.76
Net Debt to EBITDA		 0.00 -0.26 -0.07
Long-Term Debt to EBITDA		 0.00 -0.48 -0.68
Debt to NOPAT		 0.00 -1.01 -1.20
Net Debt to NOPAT		 0.00 -0.45 -0.11
Long-Term Debt to NOPAT		 0.00 -0.82 -1.07
Altman Z-Score		 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% -2.81% -3.83%
Liquidity Ratios		 - - -
Current Ratio		 0.00 1.30 2.67
Quick Ratio		 0.00 1.11 2.65
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -72 -33
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -112.39 -510.99
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -0.53 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.05
Accounts Receivable Turnover		 0.00 0.30 0.64
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 4.92 63.60
Accounts Payable Turnover		 0.00 0.00 0.36
Days Sales Outstanding (DSO)		 0.00 1,204.45 571.97
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 1,025.58
Cash Conversion Cycle (CCC)		 0.00 1,204.45 -453.61
Capital & Investment Metrics		 - - -
Invested Capital		 0.00 39 46
Invested Capital Turnover		 0.00 0.02 0.09
Increase / (Decrease) in Invested Capital		 0.00 39 6.65
Enterprise Value (EV)		 0.00 0.00 0.00
Market Capitalization		 0.00 0.00 0.00
Book Value per Share		 $0.00 $0.00 $0.02
Tangible Book Value per Share		 $0.00 $0.00 $0.00
Total Capital		 0.00 61 75
Total Debt		 0.00 33 32
Total Long-Term Debt		 0.00 27 29
Net Debt		 0.00 15 2.98
Capital Expenditures (CapEx)		 0.05 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -6.98 -0.77
Debt-free Net Working Capital (DFNWC)		 0.00 12 28
Net Working Capital (NWC)		 0.00 5.27 25
Net Nonoperating Expense (NNE)		 10 15 12
Net Nonoperating Obligations (NNO)		 0.00 12 2.98
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -2,333.79% -21.32%
Debt-free Net Working Capital to Revenue		 0.00% 3,873.86% 780.05%
Net Working Capital to Revenue		 0.00% 1,762.03% 685.88%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.76)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 2.36B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.76)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 2.36B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 2.36B
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -33 -27
Normalized NOPAT Margin		 -8,257.30% -11,044.06% -735.44%
Pre Tax Income Margin		 -11,825.59% -15,992.07% -1,052.43%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -330.17 -87.22 -646.91
NOPAT to Interest Expense		 -280.41 -51.40 -409.21
EBIT Less CapEx to Interest Expense		 -330.70 -87.22 -646.91
NOPAT Less CapEx to Interest Expense		 -280.94 -51.40 -409.21
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Radiopharm Theranostics

No quarterly metrics and ratios for Radiopharm Theranostics are available.


Financials Breakdown Chart

Radiopharm Theranostics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Radiopharm Theranostics' fiscal year ends in June. Their fiscal year 2025 ended on June 30, 2025.

Radiopharm Theranostics' net income appears to be on an upward trend, with a most recent value of -$38.34 million in 2025, rising from -$34.61 million in 2023. The previous period was -$47.95 million in 2024. See where experts think Radiopharm Theranostics is headed by visiting Radiopharm Theranostics' forecast page.

Radiopharm Theranostics' total operating income in 2025 was -$38.17 million, based on the following breakdown:
  • Total Gross Profit: $39.28 thousand
  • Total Operating Expenses: $44.40 million

Over the last 2 years, Radiopharm Theranostics' total revenue changed from $292.36 thousand in 2023 to $3.63 million in 2025, a change of 1,142.8%.

Radiopharm Theranostics' total liabilities were at $43.61 million at the end of 2025, a 2.4% decrease from 2024, and a 2.4% decrease since 2024.

In the past 1 years, Radiopharm Theranostics' cash and equivalents has ranged from $18.58 million in 2024 to $29.12 million in 2025, and is currently $29.12 million as of their latest financial filing in 2025.

Over the last 2 years, Radiopharm Theranostics' book value per share changed from 0.00 in 2023 to 0.02 in 2025, a change of 1.9%.


Related Companies

Financial statements for NASDAQ:RADX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel